GO:0071664 catenin-TCF7L2 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071664 (catenin-TCF7L2 complex) is a nuclear protein complex containing a catenin (typically beta-catenin/CTNNB1) and the transcription factor TCF7L2 (TCF4) that binds TCF DNA motifs in WNT target gene promoters.
• The complex is the terminal effector of canonical WNT/beta-catenin signaling and directly controls transcription of context-specific target genes.
• Its target repertoire is cell-type dependent and includes FERM domain-containing protein 5 (FRMD5), visinin-like 1 (VSNL1), and motile sperm domain containing 1 (MOSPD1).
• Pharmacological disruption of the beta-catenin/TCF7L2 interaction is a validated anti-tumor strategy in triple-negative breast cancer, where matrine blocks complex formation and promotes ferroptosis.
• The complex is implicated in hematological malignancies including adult T-cell leukemia and diffuse large B-cell lymphoma, and in fibrolamellar hepatocellular carcinoma.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of complex components and their target genes.
Description
The catenin-TCF7L2 complex (GO:0071664) is the nuclear effector of canonical WNT signaling, formed when a catenin, most commonly beta-catenin (CTNNB1), associates with the HMG-box transcription factor TCF7L2 (also known as TCF4) on TCF DNA motifs within WNT-responsive promoters. QuickGO defines this cellular component as a protein complex that contains a catenin and TCF7L2, binds the TCF DNA motif within a promoter element, and regulates WNT target gene transcription. Because the complex converts extracellular WNT signals into defined transcriptional programs, its composition and promoter occupancy are central to developmental and oncogenic gene regulation. Mechanistically, the complex acts as a sequence-specific transcriptional switch. When WNT signaling is active, stabilized beta-catenin enters the nucleus, binds TCF7L2, and recruits co-activators that drive target gene expression; when WNT is off, TCF7L2 instead associates with repressive cofactors. The identity of the target genes engaged by the complex is highly context dependent, which explains why the same complex can drive proliferation in one tissue and differentiation in another. For researchers, GO:0071664 provides a precise annotation target for studying WNT-driven transcription. Experimental evidence shows that the complex directly regulates genes such as FRMD5, VSNL1 and MOSPD1, and that disrupting the catenin-TCF7L2 interaction alters cancer cell phenotypes including ferroptosis sensitivity and metastatic capacity. This makes the complex both a mechanistic hub and a therapeutic node.
catenin-TCF7L2 complex At A Glance
| GO ID | GO:0071664 |
|---|---|
| GO term | catenin-TCF7L2 complex |
| Ontology | cellular_component |
| Synonym | catenin-TCF4 complex |
| Major function | Binds TCF DNA motifs in promoters and regulates WNT target gene transcription |
| Core subunits | A catenin (typically CTNNB1/beta-catenin) and TCF7L2 (TCF4) |
| DNA element | TCF DNA motif within a promoter element |
| Pathway context | Canonical WNT/beta-catenin signaling |
| Representative targets | FRMD5, VSNL1, MOSPD1 |
What Is GO:0071664?
In plain terms, GO:0071664 describes a nuclear protein machine made of two essential parts: a catenin protein (usually beta-catenin) and the transcription factor TCF7L2/TCF4. This machine sits on specific TCF DNA motifs in gene promoters and switches WNT target genes on or off. It is annotated as a cellular component because it is a physical assembly of proteins at chromatin, not a single enzyme or a whole pathway.
Why Is catenin-TCF7L2 complex Important in Cell Biology?
GO:0071664 matters because it is the point at which canonical WNT signaling becomes a specific transcriptional output. Every downstream consequence of WNT activation in a given cell depends on which catenin-TCF7L2 complexes assemble on which promoters. This makes the complex a central explanatory variable for WNT-driven proliferation, differentiation, apoptosis resistance and metastasis, and a direct pharmacological target, as shown by agents that block beta-catenin/TCF7L2 formation and suppress tumor phenotypes.
• Defines the terminal transcriptional effector step of canonical WNT/beta-catenin signaling.
• Directly controls context-specific target genes such as FRMD5, VSNL1 and MOSPD1.
• Its disruption by matrine promotes ferroptosis and inhibits metastasis in triple-negative breast cancer.
• Implicated in adult T-cell leukemia, where Hsp90 inhibitors act via the beta-catenin/TCF7L2 pathway.
• Involved in diffuse large B-cell lymphoma, where FOXP1 potentiates Wnt/beta-catenin signaling.
• Linked to fibrolamellar hepatocellular carcinoma through beta-catenin cancer-enhancing genomic regions.
• TIP5 activates beta-catenin/TCF signaling in hepatocellular carcinoma, highlighting cofactor control.
• Provides a defined annotation unit for CRISPR screens of WNT-dependent transcription.
• Enables mechanistic separation of catenin-dependent versus TCF7L2-dependent target gene regulation.
• Supports development of small molecules that selectively block complex assembly.
Structure and Composition of catenin-TCF7L2 complex
Catenin subunit (CTNNB1/beta-catenin)
In simple terms: The catenin is the activating half of the machine that carries the WNT signal into the nucleus.
The catenin subunit, most commonly beta-catenin (CTNNB1), is the signal-transducing component of GO:0071664. Upon WNT pathway activation, beta-catenin accumulates and enters the nucleus, where it binds TCF7L2 to form the complex and provides the transactivation surface required for target gene induction. Pharmacological blockade of beta-catenin prevents formation of the beta-catenin/TCF7L2 complex, demonstrating that the catenin subunit is essential for complex assembly and function.
TCF7L2 (TCF4) DNA-binding subunit
In simple terms: TCF7L2 is the part that reads the DNA address and decides which genes the machine can reach.
TCF7L2 (also called TCF4) is the sequence-specific DNA-binding subunit of the complex. It recognizes the TCF DNA motif within promoter elements, thereby positioning the catenin-TCF7L2 complex on WNT target genes. Because TCF7L2 provides promoter targeting, the complex's gene repertoire is determined by where TCF7L2 binds in a given cell type, as illustrated by the identification of FRMD5 as a direct target of the beta-catenin/TCF7L2 complex.
Promoter DNA element (TCF motif)
In simple terms: The TCF motif is the short DNA sequence in the promoter that the complex must recognize to act.
The complex is defined in part by its binding to the TCF DNA motif within a promoter element. This DNA element is the physical anchor that converts the complex from a soluble protein assembly into a chromatin-bound transcriptional regulator. Target genes such as FRMD5, VSNL1 and MOSPD1 are upregulated through WNT/beta-catenin signaling, consistent with promoter recruitment of the catenin-TCF7L2 complex.
Associated cofactors and co-regulators
In simple terms: Helper proteins attach to the core complex and tune whether genes are switched on strongly, weakly, or not at all.
The core catenin-TCF7L2 assembly operates with additional cofactors that modulate its transcriptional output. TIP5 has been shown to activate beta-catenin/transcription factor signaling in hepatocellular carcinoma, indicating that accessory proteins can enhance complex-driven transcription. FOXP1 potentiates Wnt/beta-catenin signaling in diffuse large B cell lymphoma, further demonstrating that co-regulators shape the activity of catenin-TCF7L2-dependent transcription.
Assembly in the nuclear compartment
In simple terms: The machine is built inside the nucleus, right on the genes it controls.
Assembly of GO:0071664 occurs in the nuclear compartment, where the catenin subunit and TCF7L2 converge on TCF motif-containing promoters. Nuclear complex formation is the decisive step for WNT target gene regulation, and agents that block the beta-catenin/TCF7L2 interaction act at this assembly step to alter downstream phenotypes such as ferroptosis and metastasis. The complex therefore represents a chromatin-associated, nucleus-restricted cellular component.
Key Genes Involved in GO:0071664 catenin-TCF7L2 complex
The following genes and proteins are experimentally linked to the catenin-TCF7L2 complex (GO:0071664), either as core subunits, direct target genes, or signaling modifiers documented in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTNNB1 (beta-catenin) | Catenin subunit that binds TCF7L2 and activates WNT target transcription | Core component of GO:0071664; target of complex-disrupting agents |
| TCF7L2 (TCF4) | HMG-box transcription factor that binds TCF DNA motifs and recruits catenin | Defines promoter targeting of the complex |
| FRMD5 | Direct target gene of the beta-catenin/TCF7L2 complex | Identified as a novel target of the complex |
| VSNL1 | WNT/beta-catenin target gene involved in apoptosis resistance | Links complex activity to colorectal cancer survival |
| MOSPD1 | Gene upregulated by WNT/beta-catenin signaling | Readout of complex-driven transcription in colorectal cancer |
| FOXP1 | Potentiates Wnt/beta-catenin signaling | Modifier of complex output in diffuse large B cell lymphoma |
| TIP5 | Activates beta-catenin/transcription factor signaling | Cofactor enhancing complex activity in hepatocellular carcinoma |
| HSP90 family | Chaperone support for beta-catenin/TCF7L2 pathway activity | Hsp90 inhibitors act via beta-catenin/TCF7L2 in adult T cell leukemia |
| Matrine (pharmacological probe) | Blocks formation of the beta-catenin/TCF7L2 complex | Chemical tool for disrupting GO:0071664 |
| WNT ligands (upstream) | Activate canonical signaling that stabilizes beta-catenin | Upstream input for complex assembly |
| APC (pathway context) | Negative regulator of beta-catenin stability | Pathway context for complex-driven transcription |
| CTNNB1 genomic regions | Cancer-enhancing genomic regions associated with beta-catenin | Implicated in fibrolamellar hepatocellular carcinoma |
| TCF motif-containing promoters | DNA elements bound by the complex | Define target gene specificity |
| Ferroptosis machinery | Downstream phenotype altered by complex disruption | Matrine-driven ferroptosis in triple-negative breast cancer |
| Metastasis programs | Phenotypes suppressed when complex formation is blocked | Anti-metastatic effect of complex disruption |
| Apoptosis regulators | Modulated via WNT target genes such as VSNL1 | Apoptosis resistance in colorectal cancer |
How Is catenin-TCF7L2 complex Regulated?
Regulation of the catenin-TCF7L2 complex occurs at multiple levels. Upstream, canonical WNT signaling controls the availability of the catenin subunit, since beta-catenin must accumulate and enter the nucleus to form the complex. Pharmacological regulation is exemplified by matrine, which targets beta-catenin and blocks formation of the beta-catenin/TCF7L2 complex, thereby promoting ferroptosis and inhibiting metastasis in triple-negative breast cancer. Chaperone-dependent regulation is illustrated by Hsp90 inhibitors, which exert anti-proliferative activity via the beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cofactor-dependent regulation includes FOXP1, which potentiates Wnt/beta-catenin signaling in diffuse large B cell lymphoma, and TIP5, which activates beta-catenin/transcription factor signaling in hepatocellular carcinoma. Together these layers determine how much functional complex assembles and which target genes are engaged.
catenin-TCF7L2 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CTNNB1 / TCF7L2 | Triple-negative breast cancer; ferroptosis and metastasis | CTNNB1 or TCF7L2 knockout and point-mutation breast cancer cell lines |
| CTNNB1 / TCF7L2 | Adult T cell leukemia; proliferation | Knockout of complex components in leukemia cell lines treated with Hsp90 inhibitors |
| FOXP1 / CTNNB1 | Diffuse large B cell lymphoma; Wnt potentiation | FOXP1 overexpression and knockout in lymphoma models |
| TIP5 / CTNNB1 | Hepatocellular carcinoma; beta-catenin/TCF activation | TIP5 knockout and overexpression in liver cancer cells |
| VSNL1 / MOSPD1 | Colorectal cancer; apoptosis resistance and WNT target activation | Knockout of target genes in colorectal cancer cell lines |
catenin-TCF7L2 complex in breast cancer
In triple-negative breast cancer, the beta-catenin/TCF7L2 complex is a actionable node. Matrine targets beta-catenin and blocks formation of the beta-catenin/TCF7L2 complex, which promotes ferroptosis and inhibits metastasis. This demonstrates that disrupting GO:0071664 assembly can convert a WNT-driven survival state into a cell death response, and identifies the complex as a therapeutic target in aggressive breast cancer.
catenin-TCF7L2 complex in hematological malignancies
The complex is implicated in adult T cell leukemia, where Hsp90 inhibitors show anti-proliferative activity via the beta-catenin/TCF7L2 pathway. In diffuse large B cell lymphoma, FOXP1 potentiates Wnt/beta-catenin signaling, indicating that co-regulators enhance complex-driven transcription in lymphoid malignancy. These findings link GO:0071664 to both solid and hematological tumor contexts.
catenin-TCF7L2 complex in liver cancer
In hepatocellular carcinoma, TIP5 activates beta-catenin/transcription factor signaling, supporting a role for enhanced complex activity in liver tumor biology. In fibrolamellar hepatocellular carcinoma, the beta-catenin cancer-enhancing genomic regions axis is involved in tumor development, further connecting catenin-driven transcription to liver cancer pathogenesis.
catenin-TCF7L2 complex in colorectal cancer
Colorectal cancer provides clear examples of complex target genes. Visinin-like 1 (VSNL1) is a novel target gene of the Wnt/beta-catenin signaling pathway involved in apoptosis resistance, and motile sperm domain containing 1 (MOSPD1) is upregulated by the Wnt/beta-catenin signaling pathway in colorectal cancer. These studies show how GO:0071664 activity translates into specific pro-tumor transcriptional programs.
From catenin-TCF7L2 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is CTNNB1 required for catenin-TCF7L2 complex formation and target gene expression? | CTNNB1 knockout cell line |
| Does a specific residue in beta-catenin mediate TCF7L2 binding? | Point-mutation knock-in of CTNNB1 |
| Can a disease-associated TCF7L2 variant alter target gene specificity? | Knock-in of TCF7L2 variant alleles |
| Where and when does the complex occupy promoters? | Tagged knock-in of CTNNB1 or TCF7L2 for chromatin studies |
| Does excess catenin drive WNT target genes and transformation? | Overexpression of stabilized beta-catenin |
| Which cofactors modify complex output? | Overexpression or knockout of FOXP1 or TIP5 |
How to Study the catenin-TCF7L2 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Chromatin immunoprecipitation sequencing | Promoter occupancy at TCF DNA motifs | Mapping catenin-TCF7L2 complex target genes |
| RNA sequencing | Transcriptional changes after complex perturbation | Identifying WNT target genes such as VSNL1 and MOSPD1 |
| Co-immunoprecipitation | Physical interaction between catenin and TCF7L2 | Detecting complex assembly and its disruption |
| Western blotting | Protein levels of catenin and TCF7L2 | Confirming knockout or overexpression efficiency |
| Ferroptosis assays | Lipid peroxidation and cell death | Evaluating consequences of complex disruption |
| Apoptosis assays | Cell survival and death responses | Linking WNT target genes to apoptosis resistance |
| Metastasis assays | Migration and invasion capacity | Testing anti-metastatic effects of complex blockade |
| Reporter assays | TCF motif-driven transcriptional activity | Quantifying complex-dependent transcription |
Chromatin immunoprecipitation and promoter occupancy
Because GO:0071664 is defined by binding to TCF DNA motifs in promoters, chromatin immunoprecipitation of catenin or TCF7L2 followed by sequencing is a primary method to map complex occupancy. This approach identifies direct target genes such as FRMD5 and distinguishes complex-bound promoters from indirect transcriptional effects.
Transcriptomic profiling of WNT target genes
RNA sequencing after perturbation of complex components reveals the target gene repertoire controlled by the catenin-TCF7L2 complex. Studies identifying VSNL1 and MOSPD1 as WNT/beta-catenin-responsive genes illustrate how transcriptomic profiling links complex activity to downstream biology in colorectal cancer.
Protein interaction and complex assembly assays
Co-immunoprecipitation and related interaction assays detect physical association between the catenin subunit and TCF7L2. Such assays were used to show that matrine blocks formation of the beta-catenin/TCF7L2 complex, providing direct evidence for pharmacological disruption of GO:0071664.
Phenotypic assays for ferroptosis, apoptosis and metastasis
Functional readouts connect complex disruption to cell fate. Ferroptosis and metastasis assays demonstrated the consequences of blocking beta-catenin/TCF7L2 complex formation in triple-negative breast cancer, while apoptosis resistance assays linked WNT target genes to colorectal cancer survival.
How CRISPR Can Be Used to Study GO:0071664 catenin-TCF7L2 complex
Knockout
CRISPR knockout of CTNNB1 or TCF7L2 eliminates core subunits of GO:0071664 and provides the cleanest test of complex requirement. Knockout models can determine whether target genes such as FRMD5, VSNL1 and MOSPD1 depend on the complex, and whether phenotypes such as ferroptosis sensitivity or metastasis are complex-dependent.
Point Mutation
Point-mutation models allow precise interrogation of interaction interfaces and regulatory residues within the catenin-TCF7L2 complex. Because pharmacological disruption of beta-catenin blocks complex formation, point mutants that abolish or stabilize catenin-TCF7L2 binding can separate complex assembly from other beta-catenin functions.
Knock-in
Knock-in of tags or disease-associated variants into CTNNB1 or TCF7L2 enables locus-specific studies of complex assembly and promoter occupancy. Tagged knock-in supports chromatin immunoprecipitation at endogenous expression levels, which is important because the complex is defined by binding to TCF DNA motifs in native promoters.
Overexpression
Overexpression of stabilized beta-catenin or of TCF7L2 drives constitutive catenin-TCF7L2 complex activity and WNT target gene expression. This approach is useful for modeling oncogenic WNT activation, as seen in contexts where FOXP1 or TIP5 potentiate beta-catenin/TCF signaling.
How EDITGENE Supports catenin-TCF7L2 complex Research
Researchers studying catenin-TCF7L2 complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, promoter occupancy, or downstream WNT target transcription. Establishing causality requires controlled genetic perturbation of CTNNB1, TCF7L2, their cofactors, and their target genes, followed by functional readouts such as ferroptosis, apoptosis and metastasis assays.
Contact EDITGENE today to design your custom CRISPR model for catenin-TCF7L2 complex research.
Frequently Asked Questions About catenin-TCF7L2 complex
What is the catenin-TCF7L2 complex (GO:0071664)?
It is a nuclear protein complex containing a catenin, usually beta-catenin, and the transcription factor TCF7L2 (TCF4). It binds TCF DNA motifs in promoters and regulates WNT target gene transcription.
What genes are involved in the catenin-TCF7L2 complex?
Core genes include CTNNB1 (beta-catenin) and TCF7L2 (TCF4). Direct target genes include FRMD5, VSNL1 and MOSPD1, while FOXP1 and TIP5 act as co-regulators.
What does GO:0071664 mean in gene ontology?
GO:0071664 is a cellular_component term describing a protein complex that contains a catenin and TCF7L2, binds the TCF DNA motif within a promoter element, and regulates WNT target gene transcription.
How is the catenin-TCF7L2 complex regulated?
It is regulated by upstream WNT signaling that controls catenin availability, by chaperones such as Hsp90, by cofactors such as FOXP1 and TIP5, and by pharmacological agents such as matrine that block complex formation.
What diseases are linked to the catenin-TCF7L2 complex?
It is linked to triple-negative breast cancer, adult T cell leukemia, diffuse large B cell lymphoma, hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma and colorectal cancer.
Can the catenin-TCF7L2 complex be targeted therapeutically?
Yes. Matrine targets beta-catenin and blocks formation of the beta-catenin/TCF7L2 complex, promoting ferroptosis and inhibiting metastasis in triple-negative breast cancer.
What are the direct target genes of the beta-catenin/TCF7L2 complex?
FRMD5 was identified as a novel target of the beta-catenin/TCF7L2 complex, and VSNL1 and MOSPD1 are WNT/beta-catenin-responsive genes in colorectal cancer.
How do you study the catenin-TCF7L2 complex in the lab?
Common approaches include chromatin immunoprecipitation sequencing to map promoter occupancy, RNA sequencing to define target genes, co-immunoprecipitation to detect assembly, and phenotypic assays for ferroptosis, apoptosis and metastasis.
What is the synonym for GO:0071664?
The synonym is catenin-TCF4 complex, reflecting the alternative name TCF4 for TCF7L2.
Which CRISPR models are useful for catenin-TCF7L2 complex research?
Knockout of CTNNB1 or TCF7L2, point mutations in interaction domains, tagged knock-in for chromatin studies, and overexpression of stabilized beta-catenin or cofactors such as FOXP1 and TIP5.
Conclusion
GO:0071664 (catenin-TCF7L2 complex) is the nuclear transcriptional effector of canonical WNT signaling, defined by a catenin subunit, TCF7L2, and binding to TCF DNA motifs in promoters. Its target repertoire is context dependent and includes FRMD5, VSNL1 and MOSPD1, linking complex activity to apoptosis resistance and tumor biology. Pharmacological disruption of the complex promotes ferroptosis and inhibits metastasis, establishing it as a therapeutic node in triple-negative breast cancer. Because the complex sits at the intersection of signal transduction and gene regulation, causal studies require precise genetic models. CRISPR knockout, point-mutation, knock-in and overexpression approaches, combined with chromatin and transcriptomic readouts, provide the tools needed to dissect how catenin-TCF7L2 complexes drive disease-relevant transcription.
References
- 1. Sang Y et al.. 2025. Matrine targets β-catenin and blocks the formation of β-catenin/TCF7L2 complex to promote ferroptosis and inhibit metastasis in triple-negative breast cancer.. Phytomedicine 145:157044 PMID: 40651299
- 2. Zhu C et al.. 2017. Identification of FERM domain-containing protein 5 as a novel target of β-catenin/TCF7L2 complex.. Cancer Sci 108(4):612-619 PMID: 28117551
- 3. Gulati R et al.. 2022. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.. Hepatol Commun 6(10):2950-2963 PMID: 36000549
- 4. Kurashina R et al.. 2009. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.. Cancer Lett 284(1):62-70 PMID: 19464103
- 5. Walker MP et al.. 2015. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.. Sci Signal 8(362):ra12 PMID: 25650440
- 6. Li C et al.. 2018. The transcription factor 7 like 2‑binding protein TIP5 activates β‑catenin/transcription factor signaling in hepatocellular carcinoma.. Mol Med Rep 17(6):7645-7651 PMID: 29620186
- 7. Tage H et al.. 2023. Visinin-like 1, a novel target gene of the Wnt/β-catenin signaling pathway, is involved in apoptosis resistance in colorectal cancer.. Cancer Med 12(12):13426-13437 PMID: 37096864
- 8. Horie C et al.. 2022. Motile sperm domain containing 1 is upregulated by the Wnt/β-catenin signaling pathway in colorectal cancer.. Oncol Lett 24(2):282 PMID: 35814826
